Inmune Bio Inc Stock Price, News & Analysis

INmune Bio (NASDAQ: INMB) announced that the European Patent Office has granted a patent for XPro1595, an innovative treatment for neurological disorders, including Alzheimer’s Disease. The patent, effective until 2033 and owned by Xencor, Inc., highlights XPro1595's ability to cross the blood-brain barrier, allowing less invasive peripheral administration. Clinical data suggest a 40.6% reduction in neuroinflammation in key brain regions in Alzheimer’s patients. This patent positions INmune Bio to enhance its development efforts in the European market for CNS disorders.

INmune Bio, Inc. (NASDAQ: INMB) announced a conference call scheduled for August 5, 2020, at 4:30 PM ET to discuss Q2 results for the period ending June 30, 2020. The call aims to provide insights into the company’s ongoing development of treatments targeting the innate immune system, which includes products under the DN-TNF platform and the Natural Killer Cell Priming Platform. These platforms are designed to combat various diseases including COVID-19 complications, cancer, Alzheimer's, and chronic inflammation.

INmune Bio, Inc. (NASDAQ: INMB) was featured on Fox Business News, with CEO Dr. Raymond Tesi discussing the company's planned phase two human trials for a potential COVID-19 treatment using an anti-inflammatory drug. The segment highlighted the company's focus on leveraging the patient’s innate immune system and addressing lower drug costs. INmune Bio is developing several treatments through its DN-TNF and Natural Killer Cell Priming platforms, targeting diseases such as cancer, Alzheimer's, and COVID-19 complications.

INmune Bio, Inc. (NASDAQ: INMB) announced the completion of its public offering, raising approximately $23.1 million by issuing 2,500,000 shares at $10.00 per share. The offering included 2,173,914 shares and an additional 326,086 shares sold under the underwriters' option. The proceeds are intended for general corporate purposes, specifically research and development, including clinical trials. The offering was conducted under a shelf registration statement effective since April 2020.

INmune Bio, Inc. (NASDAQ: INMB) announced pricing for its underwritten public offering of 2,173,914 shares at $10.00 each, potentially raising approximately $21.7 million before expenses. An additional 326,086 shares may be purchased by underwriters. The offering is anticipated to close by July 20, 2020. The net proceeds of around $20 million will support general corporate needs, especially research and clinical trials for their product platforms targeting immune system-related diseases.

INmune Bio, a clinical-stage biotechnology company, has announced an underwritten public offering of common stock, subject to market conditions. The offering includes a 15% over-allotment option for underwriters. Proceeds will be used for working capital, corporate purposes, and to advance the company’s product candidates. The offering will utilize an effective shelf registration statement filed with the SEC. This press release does not constitute an offer to sell or buy securities in any jurisdiction where it would be unlawful.

INmune Bio (NASDAQ: INMB) reported encouraging interim results from its Phase Ib clinical trial of XPro1595, showcasing its ability to reduce neuroinflammation in Alzheimer's patients. In comparison to a control group, patients treated with XPro1595 showed a 40.6% reduction in inflammation in the Arcuate Fasciculus and overall reductions in white matter free water, indicating potential cognitive benefits. The study aims to explore XPro1595's efficacy in targeting soluble TNF without affecting other TNF forms. The Company will discuss these findings in a KOL event scheduled for July 14, 2020.

INmune Bio, Inc. (NASDAQ: INMB) has received MHRA approval to initiate a Phase I clinical trial for INKmune, a therapy designed to activate patients' NK cells to combat high-risk Myelodysplastic Syndrome (MDS). This first-in-man trial aims to enroll 9 patients at a UK center, targeting a start in the latter half of 2020. Dr. Marion Wood emphasizes the need for better-tolerated treatment options for elderly patients unable to undergo high-dose chemotherapy. The company aims to demonstrate improved NK cell activity in patients as a novel approach to therapy.